PET-CT Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The global PET-CT market encompasses the manufacturing, distribution, and servicing of hybrid imaging devices that integrate positron emission tomography and computed tomography in a single gantry. These systems are primarily used for cancer detection, staging, and treatment monitoring, as well as cardiac and neurological assessments. Market estimates for 2025 range from approximately $2.44 billion to $2.89 billion depending on scope (device-only versus broader scanner market definitions), reflecting consistent analyst recognition of PET-CT as the leading modality within the overall PET imaging market.

• •Hybrid PET-CT systems command roughly 82-84% share of the PET scanner market in multiple regional analyses
• •The broader positron emission tomography market (including services and radiotracers) is valued significantly higher at approximately $18.7 billion in 2025, underscoring the device market as only one component of a larger ecosystem
• •The U.S. market alone is projected to reach approximately $995 million by 2030, with PET-CT holding the largest and fastest-growing segment at nearly 84% share

The primary catalyst for market expansion is the rising global burden of cancer, with organizations such as the World Health Organization citing increasing annual cancer prevalence as a key demand factor for PET-CT imaging. An aging global population further amplifies demand, as cancer incidence correlates strongly with age. Additionally, advancements in detector technology, digital imaging, and the development of novel radiotracers are expanding the clinical utility of PET-CT beyond oncology into cardiology, neurology, and pharmaceutical research.

• •WHO data on rising annual cancer prevalence is cited across multiple market analyses as a foundational demand driver
• •Advances in detector technology and digital PET systems are improving image quality and reducing scan times, driving equipment replacement cycles
• •Growing adoption of PET-CT in emerging markets, supported by increasing healthcare infrastructure investment, is broadening the addressable market

By product type, fully integrated hybrid PET-CT systems represent the dominant and fastest-growing category, consistently accounting for over 80% of scanner sales in most regional markets. Application-wise, oncology commands the largest share, followed by cardiology and neurology. Geographically, North America leads the global market, supported by high healthcare spending, favorable reimbursement policies, and advanced clinical adoption, while Asia-Pacific is emerging as the fastest-growing region due to rising healthcare access and expanding oncology infrastructure.

• •North America is the largest regional market, with the U.S. projected at roughly $995 million by 2030 at a 3.4% CAGR from 2024
• •Asia-Pacific is identified as a key growth region, driven by hospital expansion, rising cancer incidence, and growing diagnostic capabilities in countries including China, India, and Japan
• •Europe maintains a strong presence, supported by established healthcare systems and regulatory frameworks that facilitate the adoption of advanced imaging technologies

What are the recent trends and outlook?

Looking forward, the market is expected to benefit from the continued miniaturization and digitization of imaging hardware, including total-body PET scanners and AI-enhanced reconstruction algorithms that improve diagnostic accuracy. Regulatory approvals for new PET radiotracers targeting specific cancer biomarkers are also anticipated to broaden clinical indications and increase procedural volumes. Long-term growth will be shaped by the intersection of aging demographics, precision medicine initiatives, and healthcare systems' increasing emphasis on early and accurate cancer diagnosis.

• •Total-body PET technology and AI-assisted image analysis are emerging as key differentiators expected to accelerate equipment refresh cycles
• •Expanding approvals for novel radiotracers targeting prostate cancer, Alzheimer's disease, and other conditions are projected to open new application segments
• •The market is forecast to reach between $3.5 billion and $4.5 billion by 2034-2035, depending on scope and methodology, sustaining a long-term CAGR in the 4.5-6.5% range